MTOR and ovarian serous adenocarcinoma: Aberrant activation of the RAS/MAPK pathway is reported in 25% of high-grade serous ovarian cancer (HGSOC) which accounts for 70% of EOCs and PI3K/AKT/mTOR signaling is increased in ~40–50% of EOC73.